Goeckerman Therapy for Psoriasis

Recruiting in Palo Alto (17 mi)

Overseen byTina Bhutani, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 4

Waitlist Available

Sponsor: University of California, San Francisco

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?This study examines the effect of Goeckerman therapy (a combination of phototherapy and topical crude coal tar), crude coal tar alone, and phototherapy alone on the immunologic and genetic environment within psoriatic skin lesions.

Eligibility Criteria

This trial is for adults over 18 with moderate to severe plaque psoriasis, who are candidates for phototherapy or systemic therapy. They should have a Body Surface Area (BSA) affected by psoriasis of at least 5% and be able to follow the study's procedures. People with non-plaque psoriasis, drug-induced psoriasis, severe controlled psoriatic arthritis, photosensitivity disorders, immune cell abnormalities, HIV positive status or allergies to local anesthetics cannot participate.

Inclusion Criteria

You are being considered for light therapy or medication treatment.

You have a large body surface area, more than 5%.

Physical exam within clinically acceptable limits

+3 more

Exclusion Criteria

You have been diagnosed with HIV.

Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data

You have a type of psoriasis that is mostly not in the form of plaques.

+5 more

Participant Groups

The study is testing three treatments: Goeckerman Therapy (phototherapy combined with crude coal tar), crude coal tar alone, and phototherapy alone. It aims to understand how these treatments affect the immune system and genes within skin lesions caused by plaque psoriasis.

3Treatment groups

Active Control

Group I: Phototherapy OnlyActive Control1 Intervention

Patients with psoriasis who will receive narrowband ultraviolet B (NB-UVB) phototherapy 3 days per week for 12 weeks.

Group II: Crude Coal Tar OnlyActive Control1 Intervention

Patients with psoriasis who will receive skin treatment with crude coal tar only 5 days per week for 6 weeks.

Group III: Goeckerman TherapyActive Control1 Intervention

Patients with psoriasis who will receive Goeckerman therapy 5 days per week for 6 weeks.